Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital

Lifesci Capital started coverage on shares of Immunome (NASDAQ:IMNM) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage issued an outperform rating and a $20.00 target price on the stock.

A number of other equities research analysts also recently issued reports on IMNM. Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Monday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has an average rating of “Buy” and an average price target of $27.17.

Immunome Stock Performance

IMNM stock opened at $8.73 on Tuesday. Immunome has a one year low of $8.39 and a one year high of $26.70. The company’s fifty day moving average price is $10.09 and its 200-day moving average price is $11.89. The company has a market capitalization of $696.45 million, a PE ratio of -1.08 and a beta of 1.93.

Insider Activity at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. FMR LLC increased its position in Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after acquiring an additional 13,757 shares during the last quarter. Janus Henderson Group PLC increased its position in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Enavate Sciences GP LLC bought a new position in Immunome during the fourth quarter valued at $36,939,000. Price T Rowe Associates Inc. MD increased its position in Immunome by 12.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock valued at $24,243,000 after acquiring an additional 246,447 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Immunome by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock valued at $13,054,000 after acquiring an additional 21,396 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.